[{"id":"f21e2257-fc10-4287-a229-a9b90ef0e664","acronym":"","url":"https://clinicaltrials.gov/study/NCT03471663","created_at":"2021-01-18T17:06:32.250Z","updated_at":"2024-07-02T16:35:24.200Z","phase":"Phase 1","brief_title":"A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer","source_id_and_acronym":"NCT03471663","lead_sponsor":"InventisBio Co., Ltd","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • taragarestrant (D-0502)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 03/18/2018","start_date":" 03/18/2018","primary_txt":" Primary completion: 10/18/2023","primary_completion_date":" 10/18/2023","study_txt":" Completion: 10/18/2023","study_completion_date":" 10/18/2023","last_update_posted":"2024-01-08"}]